MLAB / Mesa Laboratories, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2025 MESA LABORATORIES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2025 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 MESA LABORATORIES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Number)

Prior to Payment of 2025

Exhibit 99.1 Mesa Laboratories Executes Previously-Announced Strategic Financing Plan Lakewood, CO — August 18, 2025 Mesa Laboratories, Inc. (NASDAQ: MLAB) (we, us, our, “Mesa” or the “Company”) today announced that it has executed on its previously-announced financial strategy, repaying $97.5 million aggregate principal of the Company’s 1.375% Convertible Senior Notes due August 2025 (the “2025 N

Form of Amendment to Executive Employment Agreements, by and among Mesa Laboratories, Inc. and Messrs. Owens, Sakys and Archbold

Exhibit 10.5.1 AMENDMENT TO EMPLOYMENT AGREEMENT The following Amendment (“Amendment”) to that certain [First Amended and Restated] Executive Employment Agreement dated as of September 27, 2021, by and between [named executive officer] and Mesa Laboratories, Inc. (the “Employment Agreement”), is made effective as of [effective date, 2025] (the “Effective Date”). WHEREAS, Mesa Laboratories, Inc. (t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): AUGUST 5, 2025 MESA LABORATORIES,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): AUGUST 5, 2025 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Number)

Mesa Labs Announces First Quarter Results

Exhibit 99.1 Mesa Labs Announces First Quarter Results Lakewood, Colorado, August 5, 2025 – Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its first fiscal quarter (“1Q26”) ended June 30, 2025 (amounts in thousands). First quarter FY26 compared to first quarter FY25: ● Re

United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q

Table of Contents United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No: 0-11740 MESA LAB

Form of 2026 Restricted Stock Unit Agreement, issued under the 2021 Equity Plan

Exhibit 10.3.1 Note: Do not sign and return this document to the Company. By clicking on the “ACCEPT” box, you acknowledge that you have read the information below and agree to be bound by the terms of the Plan and this Agreement. Please provide such acceptance within ninety (90) days of the Grant Date. Mesa Laboratories Inc. 2021 Equity Incentive Plan Restricted Stock Unit Award Agreement #GrantD

Form of 2026 Performance Stock Unit Agreement, issued under the 2021 Equity Plan

Exhibit 10.3.2 Note: Do not sign and return this document to the Company. By clicking on the “ACCEPT” box, you acknowledge that you have read the information below and agree to be bound by the terms of the Plan and this Agreement. Please provide such acceptance within ninety (90) days of the Grant Date. Mesa Laboratories, Inc. 2021 Equity Incentive Plan Performance Stock Unit Award Agreement #Gran

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive

Letter from Moss Adams Dated June 5, 2025

Exhibit 16.1 June 3, 2025 U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Ladies and Gentlemen: We have read the statements made by Mesa Laboratories, Inc., included under Item 4.01 of its Current Report on Form 8-K dated June 3, 2025 to be filed with the Securities and Exchange Commission. We agree with the statements concerning our Firm contained therein. Sincerely,

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2025 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Number) 84

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Form of 2025 Performance Stock Unit Agreement, issued under the 2021 Equity Incentive Plan, as Amended.

Exhibit 10.3.7 Note: Do not sign and return this document to the Company. By clicking on the “ACCEPT” box, you acknowledge that you have read the information below and agree to be bound by the terms of the Plan and this Agreement. Please provide such acceptance within ninety (90) days of the Grant Date. Mesa Laboratories, Inc. 2021 Equity Incentive Plan 2025 Performance Stock Unit Award Agreement

Mesa Labs Announces Fourth Quarter and Full Fiscal Year 2025 Results

Exhibit 99.1 Mesa Labs Announces Fourth Quarter and Full Fiscal Year 2025 Results Lakewood, Colorado, May 28, 2025 – Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its fourth fiscal quarter (“4Q25”) and full fiscal year (“FY25”) ended March 31, 2025 (amounts in thousands)

Subsidiaries of Mesa Laboratories, Inc.

Exhibit 21.1 Subsidiaries of Mesa Laboratories, Inc. March 31, 2025 The following is a listing of subsidiaries of Mesa Laboratories, Inc., a Colorado corporation Name Country of Incorporation or Organization Agena Bioscience China China Agena Bioscience GmbH Germany Agena Bioscience HK China Agena Bioscience, Inc. United States Beijing GKE Science & Technology Co. Ltd. China Gyros DE GmbH Germany

Description of securities registered under section 12.

Exhibit 4.3 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities and Exchange Act of 1934 As of March 31, 2025, Mesa Laboratories, Inc. (the “Company,” “we,” or “our”) had one class of securities, our common stock, registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The following summary of certain terms of

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2025 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Number) 84

Form of 2024 Performance Stock Unit Agreement, issued under the 2021 Equity Incentive Plan, as Amended.

Exhibit 10.3.6 Note: Do not sign and return this document to the Company. By clicking on the “ACCEPT” box, you acknowledge that you have read the information below and agree to be bound by the terms of the Plan and this Agreement. Please provide such acceptance within ninety (90) days of the Grant Date. Mesa Laboratories, Inc. 2021 Equity Incentive Plan 2024 Performance Stock Unit Award Agreement

Mesa Labs Announces Third Quarter Results

Exhibit 99.1 Mesa Labs Announces Third Quarter Results Lakewood, Colorado, February 4, 2025 – Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its third fiscal quarter (“3Q25”) ended December 31, 2024 (amounts in thousands). Third quarter FY 2025 compared to third quarter F

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): FEBRUARY 4, 2025 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Number

United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q

Table of Contents United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No: 0-11740 MESA

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): NOVEMBER 7, 2024 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Number

Mesa Labs Announces Second Quarter Results

Exhibit 99.1 Mesa Labs Announces Second Quarter Results Lakewood, Colorado, November 7, 2024 – Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its second fiscal quarter (“2Q25”) ended September 30, 2024 (amounts in thousands). Second quarter FY 2025 compared to second quar

United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q

Table of Contents United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No: 0-11740 MES

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2024 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Numbe

Letter from RSM US LLP, dated September 10, 2024.

Exhibit 16.1

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2024 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Number)

United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q

Table of Contents United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No: 0-11740 MESA LAB

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): AUGUST 5, 2024 MESA LABORATORIES,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): AUGUST 5, 2024 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Number)

Mesa Labs Announces First Quarter Results

Exhibit 99.1 Mesa Labs Announces First Quarter Results Lakewood, Colorado, August 5, 2024 – Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its first fiscal quarter (“1Q25”) ended June 30, 2024 (amounts in thousands). First quarter FY 2025 compared to first quarter FY 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive

Subsidiaries of Mesa Laboratories, Inc.

Exhibit 21.1 Subsidiaries of Mesa Laboratories, Inc. March 31, 2024 The following is a listing of subsidiaries of Mesa Laboratories, Inc., a Colorado corporation Name Country of Incorporation or Organization Agena Bioscience China China Agena Bioscience GmbH Germany Agena Bioscience HK China Agena Bioscience, Inc. United States Beijing GKE Science & Technology Co. Ltd. China GKE GmbH Germany Gyros

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Mesa Laboratories, Inc. Executive Compensation Clawback Policy

Exhibit 97.1 Mesa Laboratories, Inc. Executive Compensation Clawback Policy Purpose This Clawback Policy (this “Policy”) has been adopted by the Compensation Committee of the Board of Directors (the “Committee”) of Mesa Laboratories, Inc. (the “Company”) effective as of November 2,, 2023 (the “Effective Date”). The purpose of this Policy is to provide the Committee with the ability to recover erro

Description of securities registered under section 12.

Exhibit 4.3 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities and Exchange Act of 1934 As of March 31, 2024, Mesa Laboratories, Inc. (the “Company,” “we,” or “our”) had one class of securities, our common stock, registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The following summary of certain terms of

Mesa Laboratories, Inc. Insider Trading Policy and Standards with Respect to Confidentiality and Certain Securities Transactions

Exhibit 19.1 Insider Trading Policy and Standards with Respect to Confidentiality and Certain Securities Transactions Effective as of June 12, 2023 This Insider Trading Policy requires that employees and directors (and the others listed below) of Mesa Laboratories, Inc. and its subsidiaries (the “Company”) comply with applicable laws that prohibit persons who are aware of material nonpublic inform

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 0-11740 NOTIFICATION OF LATE FILING CUSIP NUMBER 59064R109 (Check one): ☒ Form 10-K ☐ Form 10-Q ☐ Form 20-F ☐ Form 10-D ☐ Form 11-K ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transiti

Mesa Labs Announces Fourth Quarter and Full Fiscal Year 2024 Results

Exhibit 99.1 Mesa Labs Announces Fourth Quarter and Full Fiscal Year 2024 Results Lakewood, Colorado, June 5, 2024 – Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its fourth fiscal quarter (“4Q24”) and fiscal year (“FY24”) ended March 31, 2024 (amounts in thousands). Fou

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2024 MESA LABORATORIES, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2024 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Number) 84

Amended and Restated Credit Agreement, dated as of April 5, 2024, by and among the Company, the guarantors and lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, and the joint lead arrangers and joint bookrunners party thereto. (incorporated by reference from exhibit 10.1 to the Company's Current Report on Form 8-K filed on April 8, 2024).

Exhibit 10.1 AMENDED AND RESTATED CREDIT AGREEMENT dated as of April 5, 2024 among MESA LABORATORIES, INC., The other Loan Parties Party Hereto, The Lenders Party Hereto and JPMORGAN CHASE BANK, N.A., as Administrative Agent JPMORGAN CHASE BANK, N.A., BANK OF AMERICA, N.A. and PNC CAPITAL MARKETS, LLC, as Joint Lead Arrangers and Joint Bookrunners TABLE OF CONTENTS Page ARTICLE I Definitions 2 SEC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2024 MESA LABORATORIES,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2024 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Number) 8

MESA LABS ANNOUNCES AMENDMENT TO CREDIT FACILITY AND REPURCHASE OF SENIOR CONVERTIBLE NOTES

Exhibit 99.1 MESA LABS ANNOUNCES AMENDMENT TO CREDIT FACILITY AND REPURCHASE OF SENIOR CONVERTIBLE NOTES Lakewood, Colorado, April 8, 2024 – Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced the closing of its Amended and Restated Credit Agreement (the “Credit Agreement”), which provides up to $200 million of senior secured debt through a syndicate of ban

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Number) 8

March 25, 2024

John Elofson 303.892.7335 [email protected] March 25, 2024 By EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Energy & Transportation 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Christie Wong and Ms. Kristin Lochhead Re: Mesa Laboratories, Inc. Form 10-K for the Fiscal Year Ended March 31, 2023 Filed May 30, 2023 Response Dated March 15, 2024 F

March 15, 2024

John Elofson 303.892.7335 [email protected] March 15, 2024 By EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Christie Wong and Ms. Kristen Lochhead Re: Mesa Laboratories, Inc. Form 10-K for the Fiscal Year Ended March 31, 2023 Filed May 30, 2023 File No. 001-11740

MLAB / Mesa Laboratories, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Mesa Laboratories Inc Title of Class of Securities: Common Stock CUSIP Number: 59064R109 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q

Table of Contents United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No: 0-11740 MESA

Mesa Labs Announces Third Quarter Results

Exhibit 99.1 Mesa Labs Announces Third Quarter Results Lakewood, Colorado, February 5, 2024 – Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its third fiscal quarter (“3Q24”) ended December 31, 2023. Third quarter FY 2024 compared to third quarter FY 2023: ● Revenues decr

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2024 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Number

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Number)

Mesa Laboratories Appoints Mark Capone to its Board of Directors

Exhibit 99.1 Mesa Laboratories Appoints Mark Capone to its Board of Directors Lakewood, Colorado, January 8, 2024 – Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa”, “we”, “us”, or “our”), a global leader in the design and manufacturing of life science tools and critical quality control solutions, today announced the appointment of Mark Capone to its Board of Directors (the “Board”), effective Januar

MLAB / Mesa Laboratories, Inc. / Conestoga Capital Advisors, LLC - CONESTOGA CAPITAL ADVISORS Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 10)* MESA LABORATORIES, INC (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 59064R109 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Number

Mesa Labs Announces Second Quarter Results

Exhibit 99.1 Mesa Labs Announces Second Quarter Results Lakewood, Colorado, November 6, 2023 – Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacturing of life science tools and critical quality control solutions, today announced results for its second fiscal quarter (“2Q24”) ended September 30, 2023. Second quarter FY 2024 compared to second quarter FY 2023: ● Revenu

Amendment No. 2 to Credit Agreement dated as of October 5, 2023 among the Company, the lenders party thereto, and JPMorgan Chase Bank, NA., as administrative agent.

Exhibit 10.1 AMENDMENT NO. 2 Dated as of October 5, 2023 to CREDIT AGREEMENT Dated as of March 5, 2021 THIS AMENDMENT NO. 2 (this “Amendment”) is made as of October 5, 2023 by and among Mesa Laboratories, Inc., a Colorado corporation (the “Borrower”), the other Loan Parties party hereto, the financial institutions listed on the signature pages hereof and JPMorgan Chase Bank, N.A., as Administrativ

United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q

Table of Contents United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No: 0-11740 MES

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2023 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Number)

Mesa Labs Acquires GKE-GmbH Complementary Sterilization Indicators and Healthcare Channels to Mesa’s SDC Platform

Exhibit 99.1 Mesa Labs Acquires GKE-GmbH Complementary Sterilization Indicators and Healthcare Channels to Mesa’s SDC Platform Lakewood, Colorado, October 16, 2023 – Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa”, “we”, “us” or “our”), a global leader in the design and manufacturing of life science tools and critical quality control solutions, today announced the completed acquisition of GKE-GmbH’s

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2023 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Number)

As filed with the Securities and Exchange Commission on August 30, 2023

As filed with the Securities and Exchange Commission on August 30, 2023 Registration No.

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2023 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Number)

Letter from Plante & Moran, PLLC dated August 28, 2023.

Exhibit 16.1 August 28, 2023 U.S. Securities and Exchange Commission Washington, D.C. 20549 Commissioners, We have read Item 4.01 included in the Form 8-K of Mesa Laboratories, Inc., which we understand will be filed with the Securities and Exchange Commission on or soon after August 28, 2023 in regard to its change in auditors. We agree with the statements made regarding our firm. We have no basi

Filing Fee Table.*

Exhibit 107 Calculation of Filing Fee Tables S-8 (Form Type) MESA LABORATORIES, INC.

Amended and Restated Articles of Incorporation of Mesa Laboratories, Inc. (incorporated by reference from exhibit 3.1 to the Current Report on Form 8-K filed August 25, 2023 (Commission File Number: 000-11740)).

Exhibit 3.1 ARTICLES OF INCORPORATION OF MESA LABORATORIES, INC. Mesa Laboratories, Inc., a corporation organized and existing under the laws of the State of Colorado (the “Corporation”), hereby certifies that: The present name of the Corporation is Mesa Laboratories, Inc. The Corporation was incorporated under the name “Mesa Medical Inc.” by the filing of its original Articles of Incorporation wi

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders

-03-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2023 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 MESA LABORATORIES,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Number)

Mesa Labs Announces First Quarter Results

Exhibit 99.1 Mesa Labs Announces First Quarter Results Lakewood, Colorado, August 3, 2023 – Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacturing of life science tools and critical quality control solutions, today announced results for its first fiscal quarter (“1Q24”) ended June 30, 2023. First quarter FY 2024 highlights compared to first quarter FY 2023: ● Revenu

United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q

Table of Contents United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No: 0-11740 MESA LAB

Mesa Laboratories Inc (MLAB) Vote Yes: Item #6 – Shareholder Proposal on Reporting Material Scope 1 Through 3 Greenhouse Gas Emissions Across Value Chain Annual Meeting: August 25, 2023

Main Post Office, P.O. Box 751 www.asyousow.org Berkeley, CA 94704 BUILDING A SAFE, JUST, AND SUSTAINABLE WORLD SINCE 1992 Notice of Exempt Solicitation Pursuant to Rule 14a-103 Name of the Registrant: Mesa Laboratories Inc Name of persons relying on exemption: As You Sow® Address of persons relying on exemption: Main Post Office, P.O. Box 751, Berkeley, CA 94704 Written materials are submitted pu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Description of securities registered under section 12.

Exhibit 4.3 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities and Exchange Act of 1934 As of March 31, 2023, Mesa Laboratories, Inc. (the “Company,” “we,” or “our”) had one class of securities, our common stock, registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The following summary of certain terms of

Subsidiaries of Mesa Laboratories, Inc.

Exhibit 21.1 Subsidiaries of Mesa Laboratories, Inc. March 31, 2023 The following is a listing of subsidiaries of Mesa Laboratories, Inc., a Colorado corporation Name Country of Incorporation or Organization Agena Bioscience China China Agena Bioscience GmbH Germany Agena Bioscience HK China Agena Bioscience, Inc. United States Gyros DE GmbH Germany Gyros Finans AB Sweden Gyros France Sarl France

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Number) 84

Mesa Labs Announces Unaudited Fourth Quarter and Full Fiscal Year 2023 Results

Exhibit 99.1 Mesa Labs Announces Unaudited Fourth Quarter and Full Fiscal Year 2023 Results Lakewood, Colorado, May 25, 2023 – Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacturing of life science tools and critical quality control solutions, today announced results for its fourth fiscal quarter (“4Q23”) and fiscal year (“FY23”) ended March 31, 2023. Fourth quarter

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 MESA LABORATORIES, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Number) 84-

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Number)

Mesa Laboratories, Inc. Reports Immaterial Financial Exposure to Silicon Valley Bank Closure

Exhibit 99.1 Mesa Laboratories, Inc. Reports Immaterial Financial Exposure to Silicon Valley Bank Closure Lakewood, Colorado, March 10, 2023 – Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or the “Company”) is a global leader in the design and manufacture of life science tools and critical quality control solutions. Mesa has monitored the situation at Silicon Valley Bank (“SVB”), whereby on March

MLAB / Mesa Laboratories, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01411-mesalaboratoriesinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Mesa Laboratories Inc. Title of Class of Securities: Common Stock CUSIP Number: 59064R109 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to d

United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q

Table of Contents United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No: 0-11740 MESA

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2023 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Number

Amendment No. 1 to Credit Agreement dated as of December 22, 2022 among the Company, the lenders party thereto, and JPMorgan Chase Bank, NA., as administrative agent.

Exhibit 10.1 EXECUTION VERSION AMENDMENT NO. 1 Dated as of December 22, 2022 to CREDIT AGREEMENT Dated as of March 5, 2021 THIS AMENDMENT NO. 1 (this “Amendment”) is made as of December 22, 2022 by and among Mesa Laboratories, Inc., a Colorado corporation (the “Borrower”), the financial institutions listed on the signature pages hereof and JPMorgan Chase Bank, N.A., as Administrative Agent (the “A

Mesa Labs Announces Third Quarter Results

Exhibit 99.1 Mesa Labs Announces Third Quarter Results Lakewood, Colorado, February 6, 2023 – Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacturing of life science tools and critical quality control solutions, today announced results for its third fiscal quarter (“3Q23”) ended December 31, 2022. Third quarter FY 2023 highlights compared to third quarter FY 2022: ●

MLAB / Mesa Laboratories, Inc. / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Mesa Laboratories Inc (Name of Issuer) Common Stock (Title of Class of Securities) 59064R109 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box

MLAB / Mesa Laboratories, Inc. / Conestoga Capital Advisors, LLC - CONESTOGA CAPITAL ADVISORS Passive Investment

SC 13G/A 1 mlaba911823.htm CONESTOGA CAPITAL ADVISORS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 9)* MESA LABORATORIES, INC (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 59064R109 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement)

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2022 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commi

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2022 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Numbe

MLAB / Mesa Laboratories, Inc. / Conestoga Capital Advisors, LLC - CONESTOGA CAPITAL ADVISORS Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8)* MESA LABORATORIES, INC (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 59064R109 (CUSIP Number) November 18, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Number

Mesa Laboratories, Inc. Appoints Shiraz Ladiwala as Lead Independent Director

Exhibit 99.1 Mesa Laboratories, Inc. Appoints Shiraz Ladiwala as Lead Independent Director Appointment is a Key Step in Enhancing Mesa?s Corporate Governance Lakewood, Colorado, November 4, 2022 ? Mesa Laboratories, Inc. (NASDAQ:MLAB) (?Mesa? or the ?Company?) today announced that Shiraz Ladiwala has been appointed to serve as the Lead Independent Director of its Board of Directors (?Board?), effe

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2022 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commiss

Mesa Labs Announces Second Quarter Results

Exhibit 99.1 Mesa Labs Announces Second Quarter Results Lakewood, Colorado, November 3, 2022 ? Mesa Laboratories, Inc. (NASDAQ:MLAB) today reported results for its second fiscal quarter (?2Q23?) and six months ended September 30, 2022. Financial highlights for the quarter and six months ended September 30, 2022 as compared to last year: ? Revenues increased 64% and 54%, respectively ? Operating in

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Number

United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q

Table of Contents United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No: 0-11740 MES

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2022 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materia

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materia

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): AUGUST 4, 2022 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Number)

Form of 2023 Performance Stock Unit Agreement, issued under the 2021 Equity Plan (incorporated by reference from Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed on August 4, 2022).

Exhibit 10.1 Note: Do not sign and return this document to the Company. By clicking on the ?ACCEPT? box, you acknowledge that you have read the information below and agree to be bound by the terms of the Plan and this Agreement. Please provide such acceptance within ninety (90) days of the Grant Date. Mesa Laboratories, Inc. 2021 Equity Incentive Plan Performance Stock Unit Award Agreement GrantDa

Mesa Labs Announces First Quarter Results

Exhibit 99.1 Mesa Labs Announces First Quarter Results Lakewood, Colorado, August 4, 2022 ? Mesa Laboratories, Inc. (NASDAQ:MLAB) today announced results for its first fiscal quarter (?1Q23?). Financial Results (amounts in thousands, except per share data) In comparison to the same quarter in the prior year (?1Q22?), revenues increased 44% to $50,453, operating income decreased 247% to $(4,594), a

United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q

Table of Contents United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No: 0-11740 MESA LAB

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Act of 1934

DEF 14A 1 mlab20210916def14a.htm FORM DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2022 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Number) 8

Mesa Laboratories Appoints Tony Tripeny to its Board of Directors

Exhibit 99.1 Mesa Laboratories Appoints Tony Tripeny to its Board of Directors Lakewood, Colorado, June 23, 2022 ? Mesa Laboratories, Inc. (NASDAQ:MLAB) announced the appointment of Tony Tripeny to its Board of Directors (the ?Board?), effective June 23, 2022. Tony was previously the Executive Vice President and Chief Financial Officer of Corning, Incorporated and retired on May 2, 2022. With Mr.

Mesa Labs Reports Fourth Quarter and Full Fiscal Year Results

Exhibit 99.1 Mesa Labs Reports Fourth Quarter and Full Fiscal Year Results Lakewood, Colorado, May 31, 2022 ? Mesa Laboratories, Inc. (NASDAQ:MLAB) today announced results for the fourth quarter (?4Q22?) and full year ended March 31, 2022 (?FY22?). Financial highlights for the quarter and year ended March 31, 2022, as compared to the same periods last year: ? Revenues increased 55% and 38%, respec

(incorporated by reference from Exhibit 10.3.6 to the Company's Annual Report of Form 10-K filed on May 31, 2022).

Exhibit 10.3.6 MESA LABORATORIES INC. RESTRICTED STOCK UNIT AGREEMENT (Pursuant to the 2014 Equity Plan) Version 1.2; February 4, 2019 (amended October 28, 2020) Mesa Laboratories, Inc., a Colorado corporation (the ?Company?) hereby agrees to award to the recipient named below (the ?Recipient?) restricted stock units over the number of shares of Common Stock of the Company (the ?Shares?) set forth

Subsidiaries of Mesa Laboratories, Inc.

Exhibit 21.1 Subsidiaries of Mesa Laboratories, Inc. March 31, 2022 The following is a listing of subsidiaries of Mesa Laboratories, Inc., a Colorado corporation Name Country of Incorporation or Organization Agena Bioscience China China Agena Bioscience GmbH Germany Agena Bioscience HK China Agena Bioscience, Inc. United States Gyros DE GmbH Germany Gyros Finans AB Sweden Gyros France Sarl France

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No: 0-11740 MESA LAB

Conflict Minerals Report as required by Item 1.01 and 1.02 of this Form.

Exhibit 1.01 Conflict Minerals Disclosure and Report This is the Conflict Minerals Report of Mesa Laboratories, Inc. (“Mesa”) for calendar year 2021 in accordance with Rule 13p-1 (“Rule 13p-1”) under the Securities Exchange Act of 1934 (the “1934 Act”). Please refer to Rule 13p-1, Form SD and the 1934 Act Release No. 3467716 for definitions to the terms used in this Report, unless otherwise define

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-D Specialized Disclosure Report MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter)

SD 1 mlab20220527sd.htm FORM SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-D Specialized Disclosure Report MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado 84-0872291 (State or other jurisdiction of (I.R.S. Employer Incorporation or organization) Identification number) 12100 West Sixth Avenue Lakewood, Colorado 80228 (Addre

Description of securities registered under section 12.

Exhibit 4.3 Description of the Registrant?s Securities Registered Pursuant to Section 12 of the Securities and Exchange Act of 1934 As of March 31, 2022, Mesa Laboratories, Inc. (the ?Company,? ?we,? or ?our?) had one class of securities, our common stock, registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?). The following summary of certain terms of

Mesa Laboratories, Inc 2021 Equity Incentive Plan (incorporated by reference from Exhibit 10.2.3 to the Company's Annual Form 10-K filed on May 31, 2022).

Exhibit 10.2.3 MESA LABORATORIES, INC. 2021 EQUITY INCENTIVE PLAN (Effective as of October 27, 2021, as amended) 1. ESTABLISHMENT AND PURPOSE OF PLAN Mesa Laboratories, Inc., a Colorado corporation (the ?Company?), hereby establishes the Mesa Laboratories, Inc. 2021 Equity Incentive Plan (the ?Plan?) as set forth in this document. The purpose of the Plan is to promote the success of the Company an

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2022 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado 0-11740 84-0872291 (State or other jurisdiction of incorporation) (Commission File

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2022 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Number) 8

Up to $150,000,000 Common Stock

TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(5)? ?Registration No. 333-264137? PROSPECTUS SUPPLEMENT (To Prospectus dated April 5, 2022) Up to $150,000,000 Common Stock? On April 5, 2022, we entered into an Open Market Sale AgreementSM, or the Sales Agreement, with Jefferies LLC (?Jefferies? or the ?Agent?), relating to our common shares, no par value per share, offered by this prospectus supp

Form of Indenture.

Exhibit 4.1 Mesa Laboratories, Inc. INDENTURE Dated as of [??????????] U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 4 Section 1.4 Rules of Construction 5 ARTICLE II THE SECURITIES 5 Section 2.1

Calculation of Filing Fee Tables (Form Type) Mesa Laboratories, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Mesa Laboratories, Inc.

Form T-1 Statement of Eligibility of Trustee for the Indenture.

Exhibit 25.1 securities and exchange commission Washington, D.C. 20549 FORM T-1 Statement of Eligibility Under The Trust Indenture Act of 1939 of a Corporation Designated to Act as Trustee Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2)? U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 91-1821036 I.R.S. Em

As filed with the Securities and Exchange Commission on April 5, 2022.

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on April 5, 2022.

Filing Fees

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Mesa Laboratories, Inc.

Open Market Sales AgreementSM dated April 5, 2022 by and among Mesa Laboratories, Inc and Jeffries LLC (incorporated by reference from the Company's Current Report on Form 8-K filed on April 5, 2022).

Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM April 5, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Mesa Laboratories, Inc., a Colorado corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), shares of the Company?s common st

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2022 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Number) 8

September 30,

Exhibit 99.1 Condensed Consolidated Financial Statements Agena Bioscience, Inc. For the nine months ended September 30, 2021 CONTENTS PAGE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) 2 Condensed Consolidated Statements of Mezzanine Equity and Stockholders? Equity 3 Condensed Cons

UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS FOR THE NINE MONTHS ENDED DECEMBER 31, 2021

Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS FOR THE NINE MONTHS ENDED DECEMBER 31, 2021 On October 20, 2021 (the ?Acquisition Date?), Mesa Laboratories, Inc. (?Mesa? or the ?Company?), a Colorado corporation, completed its acquisition of Agena Bioscience, Inc. (?Agena?), a Delaware corporation. Pursuant to the terms of the Agreement and Plan of Merger (the ?Merger A

EXPLANATORY NOTE

Exhibit 99.3 EXPLANATORY NOTE Mesa Laboratories, Inc. ("Mesa", "Mesa Labs", the "Company", "we", "us," "our") is filing this exhibit to reflect changes to the presentation of our financial information as set forth in our Annual Report on Form 10-K for the fiscal year ended March 31, 2021 (the ?2021 Form 10-K?), as filed with the Securities and Exchange Commission (the ?SEC?) on June 1, 2021, in or

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2022 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Number)

MLAB / Mesa Laboratories, Inc. / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Mesa Laboratories Inc (Name of Issuer) Common Stock (Title of Class of Securities) 59064R109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this

MLAB / Mesa Laboratories, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Mesa Laboratories Inc. Title of Class of Securities: Common Stock CUSIP Number: 59064R109 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed

Mesa Labs Announces Third Quarter Results

Exhibit 99.1 Mesa Labs Announces Third Quarter Results Lakewood, Colorado, February 3, 2022 ? Mesa Laboratories, Inc. (NASDAQ:MLAB) today announced results for its third fiscal quarter (?3Q22?) and nine months ended December 31, 2021. Financial highlights for the quarter and nine months ended December 31, 2021 as compared to the same periods last year: ? Revenues increased 60% and 31%, respectivel

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2022 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Number

United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q

Table of Contents United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No: 0-11740 MESA

MLAB / Mesa Laboratories, Inc. / BlackRock Inc. Passive Investment

us59064r1095012522.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 4) MESA LABORATORIES INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 59064R109 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant

MLAB / Mesa Laboratories, Inc. / Conestoga Capital Advisors, LLC - CONESTOGA CAPITAL ADVISORS Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* MESA LABORATORIES, INC (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 59064R109 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2021 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Numbe

Mesa Labs Announces New Segment Reporting

Exhibit 99.1 Mesa Labs Announces New Segment Reporting Lakewood, Colorado, December 23, 2021 ? Mesa Laboratories, Inc. (NASDAQ:MLAB) (?we,? ?us,? ?our,? ?Mesa? or the ?Company?) today announced new segment reporting which will align our reportable segments with our increased strategic focus on higher growth applications within the regulated segments of the Life Sciences Tools market. ?The acquisit

REPORT OF INDEPENDENT AUDITORS

Exhibit 99.1 Report of Independent Auditors and Consolidated Financial Statements Agena Bioscience, Inc. December 31, 2020 and 2019 CONTENTS PAGE REPORT OF INDEPENDENT AUDITORS 1?2 CONSOLIDATED FINANCIAL STATEMENTS Balance Sheets 3 Statements of Operations and Comprehensive Income (Loss) 4 Statements of Mezzanine Equity and Stockholders? Equity (Deficit) 5 Statements of Cash Flows 6 Notes to Finan

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2021 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Comm

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS

Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS On October 20, 2021 (the Acquisition Date), Mesa Laboratories, Inc. (?Mesa? or the ?Company?), a Colorado corporation, completed its acquisition of Agena Bioscience, Inc. (?Agena?), a Delaware corporation. Pursuant to the terms of the Agreement and Plan of Merger (the Merger Agreement), dated September 13, 2021, among Sky Bea

June 30,

Exhibit 99.2 Condensed Consolidated Financial Statements (Unaudited) Agena Bioscience, Inc. For the six months ended June 30, 2021 CONTENTS PAGE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) Condensed Balance Sheets 1 Condensed Statements of Operations and Comprehensive Income (Loss) 2 Condensed Statements of Mezzanine Equity and Stockholders? Equity (Deficit) 3 Condensed Statements of C

United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q

Table of Contents United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No: 0-11740 MES

Mesa Labs Announces Second Quarter Results

Exhibit 99.1 Mesa Labs Announces Second Quarter Results Lakewood, Colorado, November 4, 2021 ? Mesa Laboratories, Inc. (NASDAQ:MLAB) today reported results for its second fiscal quarter (?2Q22?) and six months ended September 30, 2021. Financial highlights for the quarter and six months ended September 30, 2021 as compared to last year: ? Revenues increased 12% and 14%, respectively ? Operating in

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Number

Leader in Corporate Development and Strategy Joins Mesa Labs Board of Directors

Exhibit 99.1 Leader in Corporate Development and Strategy Joins Mesa Labs Board of Directors Lakewood, Colorado, October 29, 2021 ? Mesa Laboratories, Inc. (NASDAQ:MLAB) announced the appointment of Shiraz Ladiwala to its Board of Directors, effective October 28, 2021. Shiraz previously worked in leadership roles at Thermo Fisher Scientific and retired on August 31, 2021. With Mr. Ladiwala?s appoi

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 28, 2021 Date of Report (Date of earliest event reported) MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Number)

Mesa Laboratories, Inc. 2021 Equity Incentive Plan CEO Special Performance Stock Unit Award Agreement with Gary Owens dated October 28, 2021.

Exhibit 10.3.6 Note: Do not sign and return this document to the Company. By clicking on the ?ACCEPT? box, you acknowledge that you have read the information below and agree to be bound by the terms of the Plan and this Agreement. Please provide such acceptance within ninety (90) days of the Grant Date. Mesa Laboratories, Inc. 2021 Equity Incentive Plan CEO Special Performance Stock Unit Award Agr

Mesa Labs Closes Acquisition of Agena Bioscience

Exhibit 99.1 Mesa Labs Closes Acquisition of Agena Bioscience Lakewood, Colorado, October 20, 2021 ? Mesa Laboratories, Inc. (NASDAQ:MLAB) today announced that it has completed the previously announced acquisition of Agena Biosciences, Inc. With this highly strategic acquisition, Agena?s innovative approach to molecular diagnostics is now paired with Mesa?s proven approach to continuous improvemen

Regulation FD Disclosure, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2021 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Number

Executive Employment Agreement dated as of September 29, 2021, by and among Mesa Laboratories, Inc. and Brian Archbold

Exhibit 10.5.4 EXECUTIVE EMPLOYMENT AGREEMENT Mesa Laboratories, Inc. This Executive Employment Agreement (the ?Agreement?) is entered into on September 29, 2021 (the ?Effective Date?) by and between Mesa Laboratories, Inc. (the ?Company?) and Brian Archbold (?Executive?). 1. Employment of Executive; Position and Duties. As of the Effective Date, Executive shall be employed by the Company as Senio

First Amended and Restated Executive Employment Agreement dated as of September 29, 2021, by and among Mesa Laboratories, Inc. and Gary Owens

Exhibit 10.5.1 FIRST AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT Mesa Laboratories, Inc. This First Amended and Restated Executive Employment Agreement (the ?Agreement?) is entered into on September 29, 2021 (the ?Effective Date?) by and between Mesa Laboratories, Inc. (the ?Company?) and Gary M. Owens (?Executive?), and amends and restates in its entirety the Executive Employment Agreemen

First Amended and Restated Executive Employment Agreement dated as of September 29, 2021, by and among Mesa Laboratories, Inc. and John Sakys

Exhibit 10.5.2 FIRST AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT Mesa Laboratories, Inc. This First Amended and Restated Executive Employment Agreement (the ?Agreement?) is entered into on September 29, 2021 (the ?Effective Date?) by and between Mesa Laboratories, Inc. (the ?Company?) and John Sakys (?Executive?), and amends and restates in its entirety the Executive Employment Agreement b

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 24, 2021 Date of Report (Date of earliest event reported) MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Numbe

Executive Employment Agreement dated as of September 29, 2021, by and among Mesa Laboratories, Inc. and Greg DiNoia

Exhibit 10.5.3 EXECUTIVE EMPLOYMENT AGREEMENT Mesa Laboratories, Inc. This Executive Employment Agreement (the ?Agreement?) is entered into on September 29, 2021 (the ?Effective Date?) by and between Mesa Laboratories, Inc. (the ?Company?) and Greg DiNoia (?Executive?). 1. Employment of Executive; Position and Duties. As of the Effective Date, Executive shall be employed by the Company as Senior V

Agreement and Plan of Merger by and Among Mesa Laboratories, Inc., Sky Bearer Corp., Agena Bioscience, Inc., and Telegraph Hill Partners Management Company, LLC as the Securityholders’ Representative

Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER BY AND AMONG MESA LABORATORIES, INC., SKY BEARER CORP., AGENA BIOSCIENCE, INC. AND TELEGRAPH HILL PARTNERS MANAGEMENT COMPANY LLC, AS THE SECURITYHOLDERS? REPRESENTATIVE September 13, 2021 Article I THE MERGER 1 1.1 The Merger 1 1.2 Closing; Effective Time 2 1.3 Effect of the Merger 2 1.4 Closing Deliveries 2 1.5 Certificate of Incorporati

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2021 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Numb

Mesa Labs Announces Agreement to Acquire Agena Bioscience, Inc.

Exhibit 99.1 Mesa Labs Announces Agreement to Acquire Agena Bioscience, Inc. Lakewood, Colorado, September 14, 2021 ? Mesa Laboratories, Inc. (NASDAQ:MLAB) (?we?, ?us?, ?our?, ?Mesa? or the ?Company?), a global leader in the design and manufacturing of critical quality control solutions for the pharmaceutical, healthcare, and medical device industries, announced today that it has entered into a de

Investor Presentation by Mesa Laboratories, Inc. dated September 14, 2021

Exhibit 99.2

Current Report

4864270.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2021 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission Fi

Mesa Laboratories, Inc. 2021 Equity Incentive Plan

Exhibit 10.2.3 MESA LABORATORIES, INC. 2021 EQUITY INCENTIVE PLAN Table of Contents Page 1. ESTABLISHMENT AND PURPOSE OF PLAN 1 2. DEFINITIONS 1 2.1 Defined Terms 1 2.2 Construction 6 3. PLAN ADMINISTRATION 6 3.1 Plan Administrator 6 3.2 Powers of the Administrator 6 3.3 Binding Determinations 8 3.4 Reliance on Experts 8 3.5 Delegation of Non-Discretionary Functions 8 4. SHARES OF COMMON STOCK SUB

Form of 2021 Equity Incentive Plan Restricted Stock Unit Agreement*

Exhibit 10.38 Note: Do not sign and return this document to the Company. By clicking on the ?ACCEPT? box, you acknowledge that you have read the information below and agree to be bound by the terms of the Plan and this Agreement. Please provide such acceptance within ninety (90) days of the Grant Date. Mesa Laboratories Inc. 2021 Equity Incentive Plan Restricted Stock Unit Award Agreement Date Nam

As filed with the Securities and Exchange Commission on August 30, 2021

As filed with the Securities and Exchange Commission on August 30, 2021 Registration No.

Form of 2021 Equity Incentive Plan Option Award Agreement*

Exhibit 10.37 Note: Do not sign and return this document to the Company. By clicking on the ?ACCEPT? box, you acknowledge that you have read the information below and agree to be bound by the terms of the Plan and this Agreement. Please provide such acceptance within ninety (90) days of the Grant Date. Mesa Laboratories, Inc. 2021 Equity Incentive Plan Stock Option Award Agreement Date Name Addres

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2021 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Number)

United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q

Table of Contents United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No: 0-11740 MESA LAB

Mesa Labs Announces First Quarter Results

Exhibit 99.1 Mesa Labs Announces First Quarter Results Lakewood, Colorado, August 5, 2021 ? Mesa Laboratories, Inc. (NASDAQ:MLAB) today reported results for its first fiscal quarter (?1Q22?). Financial highlights for the quarter ended June 30, 2021 as compared to last year: ? Revenues increased 17% ? Operating income decreased 13% ? Non-GAAP adjusted operating income1 excluding unusual items incre

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Number)

Registrant’s definitive proxy statement on Schedule 14A

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive

Description of securities registered under section 12

Exhibit 4.3 Description of the Registrant?s Securities Registered Pursuant to Section 12 of the Securities and Exchange Act of 1934 As of March 31, 2021, Mesa Laboratories, Inc. (the ?Company,? ?we,? or ?our?) had one class of securities, our common stock, registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?). The following summary of certain terms of

Form of 2021 Restricted Stock Unit Agreement, issued under the 2014 Equity Plan

Exhibit 10.3.6 MESA LABORATORIES INC. RESTRICTED STOCK UNIT AGREEMENT (Pursuant to the 2014 Equity Plan) Version 1.2; February 4, 2019 (amended October 28, 2020) Mesa Laboratories, Inc., a Colorado corporation (the ?Company?) hereby agrees to award to the recipient named below (the ?Recipient?) restricted stock units over the number of shares of Common Stock of the Company (the ?Shares?) set forth

Subsidiaries of Mesa Laboratories, Inc.

Exhibit 21.1 Subsidiaries of Mesa Laboratories, Inc. March 31, 2021 The following is a listing of subsidiaries of Mesa Laboratories, Inc., a Colorado corporation Name Country of Incorporation or Organization Gyros DE GmbH Germany Gyros Finans AB Sweden Gyros France Sarl France Gyros Japan KK Japan Gyros Patent AB Sweden Gyros Protein Technology AB Sweden Gyros Protein Technology Holding AB Sweden

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No: 0-11740 MESA LAB

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2021 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Number) 84

Mesa Labs Reports Fourth Quarter and Full Fiscal Year Results

Exhibit 99.1 Mesa Labs Reports Fourth Quarter and Full Fiscal Year Results Lakewood, Colorado, June 1, 2021 ? Mesa Laboratories, Inc. (NASDAQ:MLAB) today announced results for the fourth quarter (?4Q21?) and full year ended March 31, 2021 (?FY21?). Financial highlights for the quarter and year ended March 31, 2021 as compared to last year: ? Revenues increased 11% and 14%, respectively ? Operating

Conflict Minerals Report as required by Item 1.01 and 1.02 of this Form.

Exhibit 1.01 Conflict Minerals Disclosure and Report This is the Conflict Minerals Report of Mesa Laboratories, Inc. (?Mesa?) for calendar year 2020 in accordance with Rule 13p-1 (?Rule 13p-1?) under the Securities Exchange Act of 1934 (the ?1934 Act?). Please refer to Rule 13p-1, Form SD and the 1934 Act Release No. 3467716 for definitions to the terms used in this Report, unless otherwise define

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-D Specialized Disclosure Report MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-D Specialized Disclosure Report MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado 84-0872291 (State or other jurisdiction of (I.R.S. Employer Incorporation or organization) Identification number) 12100 West Sixth Avenue Lakewood, Colorado 80228 (Address of principal executive office

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 5, 2021 Date of Report (Date of earliest event reported) MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Number) 84

Credit Agreement dated as of March 5, 2021 among Mesa Laboratories, Inc., the lenders party thereto, and JPMorgan Chase Bank, N.A., as administrative agent

Exhibit 10.1 EXECUTION VERSION CREDIT AGREEMENT dated as of March 5, 2021 among MESA LABORATORIES, INC., The other Loan Parties Party Hereto, The Lenders Party Hereto and JPMORGAN CHASE BANK, N.A., as Administrative Agent JPMORGAN CHASE BANK, N.A., as Sole Bookrunner and Sole Lead Arranger TABLE OF CONTENTS Page ARTICLE I Definitions 1 SECTION 1.01. Defined Terms 1 SECTION 1.02. Classification of

SCHEDULE 13G

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Mesa Laboratories Inc (Name of Issuer) Common Stock (Title of Class of Securities) 59064R109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc

JOINT FILING AGREEMENT

Invesco Joint Filing Agreement JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) (l) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing of the attached Schedule 13G, and any and all amendments thereto, and expressly authorize Invesco Ltd.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)*

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Mesa Laboratories Inc. Title of Class of Securities: Common Stock CUSIP Number: 59064R109 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed

Quarterly Report - FORM 10-Q

Table of Contents United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No: 0-11740 MESA

Mesa Labs Reports Third Quarter Results for FY21

Exhibit 99.1 Mesa Labs Reports Third Quarter Results for FY21 Lakewood, Colorado, February 3, 2021 – Mesa Laboratories, Inc. (NASDAQ:MLAB) today announced results for the third quarter (“3Q21”) and nine months ended December 31, 2020. Financial highlights for the quarter and nine months ended December 31, 2020 as compared to last year: ● Revenues increased 8% and 15%, respectively ● Operating inco

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2021 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* MESA LABORATORIES, INC (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 590

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* MESA LABORATORIES, INC (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 59064R109 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua

Mesa Labs Reports Second Quarter Results for FY21

Exhibit 99.1 Mesa Labs Reports Second Quarter Results for FY21 Lakewood, Colorado, November 5, 2020 – Mesa Laboratories, Inc. (NASDAQ:MLAB) today announced results for the second quarter (“2Q21”) and six months ended September 30, 2020. Financial highlights for the quarter and six months ended September 30, 2020 as compared to last year: ● Revenues increased 25% and 19%, respectively ● Operating i

Quarterly Report - FORM 10-Q

Table of Contents United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No: 0-11740 MES

Results of Operations and Financial Condition - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November5, 2020 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Number)

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 28, 2020 Date of Report (Date of earliest event reported) MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Numbe

- FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2020 MESA LABORATORIES, INC. /CO (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-11740 (Commission File Num

- FORM DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive

Quarterly Report - FORM 10-Q

Table of Contents United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No: 0-11740 MESA LAB

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2020 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) COLORADO (State or other jurisdiction of incorporation) 0-11740 (Commission File Number)

Mesa Labs Reports First Quarter Results

Exhibit 99.1 Mesa Labs Reports First Quarter Results Lakewood, Colorado, August 6, 2020 – Mesa Laboratories, Inc. (NASDAQ:MLAB) today announced results for the first quarter (“1Q21”). Financial highlights for the quarter ended June 30, 2020 as compared to last year: ● Revenues increased 14% ● Operating income decreased 41% ● Non-GAAP adjusted operating income1 excluding unusual items decreased 2%

- FORM DEF 14A

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive

Underwriting Agreement, dated June 9, 2020, by and among Mesa Laboratories, Inc., Jefferies LLC and J.P. Morgan Securities LLC.

Exhibit 1.1 Execution Version 600,000 Shares Mesa Laboratories, Inc. UNDERWRITING AGREEMENT June 9, 2020 JEFFERIES LLC J.P. MORGAN SECURITIES LLC As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o J.P. MORGAN SECURITIES LLC 383 Madison Avenue New York, New York 10179 Ladies and Gentlemen: Introductory. Mesa Laboratories, Inc., a Colorad

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2020 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) COLORADO (State or other jurisdiction of incorporation) 0-11740 (Commission File Number) 84

CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be registered(1) Proposed maximum offering price per security Proposed maximum aggregate offering price Amount of registration fee(2) Common Stock, no par va

Use these links to rapidly review the document Table of Contents TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No.

SUBJECT TO COMPLETION, DATED JUNE 8, 2020

Use these links to rapidly review the document Table of Contents TABLE OF CONTENTS Table of Contents The information contained in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed.

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2020 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) COLORADO (State or other jurisdiction of incorporation) 0-11740 (Commission File Number) 84

Annual Report - FORM 10-K

` Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Subsidiaries of Mesa Laboratories, Inc. March 31, 2020 The following is a listing of subsidiaries of Mesa Laboratories, Inc., a Colorado corporation

Exhibit 21.1 Subsidiaries of Mesa Laboratories, Inc. March 31, 2020 The following is a listing of subsidiaries of Mesa Laboratories, Inc., a Colorado corporation Name Country of Incorporation or Organization Gyros DE GmbH Germany Gyros Finans AB Sweden Gyros France Sarl France Gyros Japan KK Japan Gyros Patent AB Sweden Gyros Protein Technology AB Sweden Gyros Protein Technology Holding AB Sweden

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2020 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) COLORADO (State or other jurisdiction of incorporation) 0-11740 (Commission File Number) 84

Mesa Labs Reports Fourth Quarter and Full Fiscal Year Results

Exhibit 99.1 Mesa Labs Reports Fourth Quarter and Full Fiscal Year Results Lakewood, Colorado, June 1, 2020 – Mesa Laboratories, Inc. (NASDAQ:MLAB) today announced results for the fourth quarter (“4Q20”) and full year ended March 31, 2020 (“FY20”). Financial highlights for the quarter and year ended March 31, 2020 as compared to last year: ● Revenues increased 29% and 14%, respectively ● Operating

Description of securities registered under section 12

Exhibit 4.3 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities and Exchange Act of 1934 As of March 31, 2020, Mesa Laboratories, Inc. (the “Company,” “we,” or “our”) had one class of securities, our common stock, registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The following summary of certain terms of

Investor Presentation dated June 1, 2020

Exhibit 99.1

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 1, 2020 Date of Report (Date of earliest event reported) MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) COLORADO (State or other jurisdiction of incorporation) 0-11740 (Commission File Number) 84-

- FORM SD

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-D Specialized Disclosure Report MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Colorado 84-0872291 (State or other jurisdiction of (I.R.S. Employer Incorporation or organization) Identification number) 12100 West Sixth Avenue Lakewood, Colorado 80228 (Address of principal executive office

Exhibit 1.01 — Conflict Minerals Report as required by Item 1.01 and 1.02 of this Form.

Exhibit 1.01 Conflict Minerals Disclosure and Report This is the Conflict Minerals Report of Mesa Laboratories, Inc. (“Mesa”) for calendar year 2019 in accordance with Rule 13p-1 (“Rule 13p-1”) under the Securities Exchange Act of 1934 (the “1934 Act”). Please refer to Rule 13p-1, Form SD and the 1934 Act Release No. 3467716 for definitions to the terms used in this Report, unless otherwise define

Life Sciences Executive Shannon Hall Joins Mesa Labs Board of Directors

Exhibit 99.1 Life Sciences Executive Shannon Hall Joins Mesa Labs Board of Directors Lakewood, Colorado, May 15, 2020 – Mesa Laboratories, Inc. (NASDAQ:MLAB) today announced the election of Shannon Hall to its Board of Directors. Shannon previously led the Life Sciences business at Bio-Rad Laboratories. Ms. Hall’s election fills the open position created by the retirement of Robert Dwyer, a positi

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 11, 2020 Date of Report (Date of earliest event reported) MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) COLORADO (State or other jurisdiction of incorporation) 0-11740 (Commission File Number) 84-

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2020 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) COLORADO (State or other jurisdiction of incorporation) 0-11740 (Commission File Number) 8

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2020 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) COLORADO (State or other jurisdiction of incorporation) 0-11740 (Commission File Number)

MLAB / Mesa Laboratories, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Mesa Laboratories Inc Title of Class of Securities: Common Stock CUSIP Number: 59064R109 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ R

MLAB / Mesa Laboratories, Inc. 10-Q - Quarterly Report - FORM 10-Q

Table of Contents United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No: 0-11740 MESA

Mesa Labs Reports Third Quarter Results

Exhibit 99.1 Mesa Labs Reports Third Quarter Results Lakewood, Colorado, February 10, 2020 – Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, or “Mesa Labs”) today reported third quarter results for the three months ended December 31, 2019. Financial Results (amounts in thousands, except per share data) In comparison to the same quarter in the prior year, third quarter revenues increased 19% to

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2020 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) COLORADO (State or other jurisdiction of incorporation) 0-11740 (Commission File Numbe

MLAB / Mesa Laboratories, Inc. / Conestoga Capital Advisors, LLC - CONESTOGA CAPITAL ADVISORS Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* MESA LABORATORIES, INC (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 59064R109 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua

Condensed Consolidated Income Statement

Exhibit 99.4 Condensed Consolidated Income Statement Six Months Ended June 30, Six Months Ended June 30, Notes 2019 2018 Revenues 2 SEK 149,638,669 SEK 124,484,692 Cost of goods and services sold 50,157,727 44,553,805 Gross profit 99,480,942 79,930,887 Operating expenses: Selling 49,644,498 44,647,859 Administrative expenses 49,091,255 11,517,925 Research and development expenses 30,345,642 25,969

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2019 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) COLORADO (State or other jurisdiction of incorporation) 0-11740 (Commission File Numb

UNAUDITED PRO FORMA FINANCIAL INFORMATION

Exhibit 99.2 UNAUDITED PRO FORMA FINANCIAL INFORMATION On October 31, 2019, Mesa Laboratories, Inc. (“Mesa” or the “Company”) completed the acquisition of Gyros Protein Technologies Holding AB (“GPT”) (the “Acquisition”). The following unaudited pro forma condensed combined financial information (the “pro formas”) is based on the historical consolidated financial statements of Mesa and the histori

Gyros Protein Technologies Holding AB Consolidated Financial Statements for the financial years 2018 and 2017 The Board of Directors and Chief Executive Officer of Gyros Protein Technologies Holding AB hereby present the Consolidated Financial Statem

Exhibit 99.3 Gyros Protein Technologies Holding AB Consolidated Financial Statements for the financial years 2018 and 2017 The Board of Directors and Chief Executive Officer of Gyros Protein Technologies Holding AB hereby present the Consolidated Financial Statements for the financial years January 1 – December 31 2018 and 2017 Contents: page Independent Auditor's Report 1 Consolidated Income Stat

MLAB / Mesa Laboratories, Inc. 10-Q/A - Quarterly Report - FORM 10-Q/A

United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No: 0-11740 MESA LAB

MLAB / Mesa Laboratories, Inc. CORRESP - -

Via EDGAR December 13, 2019 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

MLAB / Mesa Laboratories, Inc. 10-Q/A - Quarterly Report - FORM 10-Q/A

United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No: 0-11740 MES

MLAB / Mesa Laboratories, Inc. 10-K/A - Annual Report - FORM 10-K/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 2 (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No: 0-11740 MESA LAB

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 2, 2019 Date of Report (Date of earliest event reported) MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) COLORADO (State or other jurisdiction of incorporation) 0-11740 (Commission File Number)

Power Point Presentation dated December 2, 2019

Exhibit 99.1

MLAB / Mesa Laboratories, Inc. 10-Q - Quarterly Report - FORM 10-Q

Table of Contents United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No: 0-11740 MES

Mesa Labs Reports Record Second Quarter Revenues and Adjusted Operating Income

Exhibit 99.1 Mesa Labs Reports Record Second Quarter Revenues and Adjusted Operating Income Lakewood, Colorado, November 6, 2019 – Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today reported record second quarter revenues and adjusted operating income1 (“AOI”) for the three months ended September 30, 2019. Financial Highlights In comparison to the same quarter in th

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2019 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) COLORADO (State or other jurisdiction of incorporation) 0-11740 (Commission File Number

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2019 MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) COLORADO (State or other jurisdiction of incorporation) 0-11740 (Commission File Number

Sale and Purchase Agreement, by and between Goldcup 19534 AB (u.n.c. to Mesa Sweden Holdco AB), Mesa Laboratories, Inc., SLS Invest AB, Ampersand 2014 Limited Partnership, and the other Sellers thereto, dated October 31, 2019.

Exhibit 10.1 Table of Contents EXECUTION VERSION CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMISSIONS ARE DESIGNATED [***]. SALE AND PURCHASE AGREEMENT THE SELLERS and THE BUYER regarding the shares in GYROS PROTEIN TECHNOLOGIES HOLDING AB 31 October 2019 1 Table of Contents T

Investor presentation of Mesa Labs, dated October 31, 2019.

Exhibit 99.2

Mesa Labs Acquires Gyros Protein Technologies

Exhibit 99.1 Mesa Labs Acquires Gyros Protein Technologies Lakewood, Colorado, October 31, 2019 – Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”), a diversified supplier of quality control instruments and consumables to highly regulated markets today announced the acquisition of Gyros Protein Technologies Holding AB (“GPT”). GPT is headquartered in Uppsala, Sweden and

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2019 (October 30, 2019) MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) COLORADO (State or other jurisdiction of incorporation) 0-11740 (Com

MLAB / Mesa Laboratories, Inc. DEFA14A - - FORM DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive

MLAB / Mesa Laboratories, Inc. DEF 14A - - FORM DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materia

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 14, 2019 Date of Report (Date of earliest event reported) MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) COLORADO (State or other jurisdiction of incorporation) 0-11740 (Commission File Number)

Power Point Presentation dated August 14, 2019

Exhibit 99.1

First Supplemental Indenture, dated August 12, 2019, by and between the Company and Wells Fargo Bank, National Association, as Trustee (incorporated by reference from Exhibit 4.2 to the Company's Current Report on Form 8-K filed on August 12, 2019).

Exhibit 4.2 EXECUTION VERSION MESA LABORATORIES, INC. and WELLS FARGO BANK, NATIONAL ASSOCIATION as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of August 12, 2019 To INDENTURE, dated as of August 12, 2019 1.375% Convertible Senior Notes due 2025 CROSS REFERENCE TABLE* Trust Indenture Act Section Indenture Section 310 (a)(1) N/A (a)(2) N/A (a)(3) N/A (a)(4) N/A (a)(5) N/A (b) N/A (c) N/A 311(a) N

Base Indenture, dated August 12, 2019, by and between the Company and Wells Fargo Bank, National Association, as Trustee (incorporated by reference from Exhibit 4.1 to the Company's Current Report on Form 8-K filed on August 12, 2019).

Exhibit 4.1 Mesa Laboratories, Inc. INDENTURE Dated as of August 12, 2019 Wells Fargo Bank, National Association Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Incorporation by Reference of Trust Indenture Act 5 Section 1.3 Rules of Construction 5 ARTICLE II THE SECURITIES 6 Section 2.1 Issuable in Series 6 Section 2.2 Es

Underwriting Agreement, by and between Mesa Laboratories, Inc., Jefferies LLC and J.P. Morgan Securities LLC, dated August 7, 2019, related to the Common Stock.

Exhibit 1.1 375,000 Shares Mesa Laboratories, Inc. UNDERWRITING AGREEMENT August 7, 2019 JEFFERIES LLC J.P. MORGAN SECURITIES LLC As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o J.P. MORGAN SECURITIES LLC 383 Madison Avenue New York, New York 10179 Ladies and Gentlemen: Introductory. Mesa Laboratories, Inc., a Colorado corporation (t

Underwriting Agreement, by and between Mesa Laboratories, Inc., Jefferies LLC and J.P. Morgan Securities LLC, dated August 7, 2019, related to the Notes.

Exhibit 1.2 1.375% Convertible Senior Notes due 2025 Mesa Laboratories, Inc. UNDERWRITING AGREEMENT August 7, 2019 JEFFERIES LLC J.P. MORGAN SECURITIES LLC As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o J.P. MORGAN SECURITIES LLC 383 Madison Avenue New York, New York 10179 Ladies and Gentlemen: Introductory. Mesa Laboratories, Inc.,

Amendment No. 3, dated August 7, 2019, to that certain Credit Agreement, dated as of March 1, 2017 between Mesa Laboratories, Inc., JPMorgan Chase Bank, N.A., as administrative agent, and the other lenders referred to therein

Exhibit 10.1 EXECUTION COPY AMENDMENT NO. 3 Dated as of August 7, 2019 to CREDIT AGREEMENT Dated as of March 1, 2017 THIS AMENDMENT NO. 3 (this “Amendment”) is made as of August 7, 2019 by and among Mesa Laboratories, Inc., a Colorado corporation (the “Borrower”), the financial institutions listed on the signature pages hereof and JPMorgan Chase Bank, N.A., as Administrative Agent (the “Administra

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 AUGUST 7, 2019 Date of Report (Date of earliest event reported) MESA LABORATORIES, INC. (Exact name of registrant as specified in its charter) COLORADO 0-11740 84-0872291 (State or other jurisdiction of incorporation) (Commission Fil

Calculation of Registration Fee Title of each class of securities to be registered Amount to be registered(1) Proposed maximum offering price per unit(2) Proposed maximum aggregate offering price(2) Amount of registration fee 1.375% Convertible Senio

Use these links to rapidly review the document Table of Contents TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No.

CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered(1) Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, no par value

Use these links to rapidly review the document Table of Contents TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No.

PRICING TERM SHEET August 7, 2019 Mesa Laboratories, Inc. Offerings of 375,000 shares of Common Stock $150,000,000 Aggregate Principal Amount of 1.375% Convertible Senior Notes due 2025

Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No. 333-233042 Dated August 7, 2019 Supplementing the Preliminary Prospectus Supplements Dated August 6, 2019 (To the Prospectus Dated August 6, 2019) PRICING TERM SHEET August 7, 2019 Mesa Laboratories, Inc. Offerings of 375,000 shares of Common Stock and $150,000,000 Aggregate Principal Amount of 1.375% Convertible Senior

$150,000,000 % Convertible Senior Notes due 2025 Mesa Laboratories, Inc.

Use these links to rapidly review the document Table of Contents TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No.